Head to Head Survey: Qualigen Therapeutics (AIXC) and Its Competitors

Qualigen Therapeutics (NASDAQ:AIXC) is one of 448 public companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its competitors? We will compare Qualigen Therapeutics to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.

Volatility and Risk

Qualigen Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Qualigen Therapeutics’ competitors have a beta of 5.82, meaning that their average stock price is 482% more volatile than the S&P 500.

Insider and Institutional Ownership

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 39.4% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 13.5% of shares of all “Pharmaceutical Preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Qualigen Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-52.57%
Qualigen Therapeutics Competitors	-2,663.64%	-364.33%	-43.21%

Analyst Ratings

This is a breakdown of recent recommendations for Qualigen Therapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1	0	0	0	1.00
Qualigen Therapeutics Competitors	4921	9984	15999	377	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 55.61%. Given Qualigen Therapeutics’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Qualigen Therapeutics has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares Qualigen Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Qualigen Therapeutics	N/A	-$6.26 million	-0.19
Qualigen Therapeutics Competitors	$430.65 million	-$67.09 million	-12.12

Qualigen Therapeutics’ competitors have higher revenue, but lower earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Qualigen Therapeutics competitors beat Qualigen Therapeutics on 9 of the 13 factors compared.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.